Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US

Sigma-1 Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX 2-73 in a Fragile X Model.

Anavex2-73, PIPELINEBy alessandroJune 11, 2016

Gordon Research Conference for Fragile X and Autism-Related Disorders, Mount Snow, VT Patricia Cogram, Daniel Klamer, Nell Rebowe, Jeffrey Sprouse, Christopher U. Missling View Poster

AAT Presentation

Anavex2-73, PIPELINEBy alessandroJune 11, 2016

14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Christopher U. Missling, PhD View Presentation

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top